Skip to main content
Erschienen in: Comparative Clinical Pathology 6/2015

01.11.2015 | Original Article

Mutation screening of exon 9 of DR5 receptor in patients with breast cancer using PCR-SSCP

verfasst von: Sh. Amirijavid, A. Akbarzadeh, S. Saghafi Jokar, S. Esmaeilian, E. Farahani, S. Ghassemi

Erschienen in: Comparative Clinical Pathology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is the most common malignant tumor and the first leading cause of cancer-related deaths in women worldwide. Cancer is the disease that spreads on the basis of uncontrolled division rate of cells. It is now clear that some oncogenic mutations disrupt apoptosis, leading to tumor initiation, progression, or metastasis. The p53-induced apoptosis is an important biological process to prevent the development of cancer. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine that preferentially induces apoptosis in tumor cells compared with normal cells through two receptors (DR4 and DR5). In the present study, we investigated genetic alterations of exon 9 of the DR5 gene as a p53-responsive gene in 30 breast cancer cases in Iran. The synthesized complementary DNA (cDNA) from extracted RNAs was determined by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP). PCR reaction and the results were analyzed using acrylamide gel and subsequently sequenced. PCR-SSCP showed significant different migration patterns in exon 9 of the DR5 in seven of the samples. Sequencing results of the seven samples and control sequence of exon 9 (National Center for Biotechnology Information, NCBI) were aligned using CLC Genomics Workbench. Five samples had same alternations in the two positions including G60 and C122. Alternations including substitution, duplication, and deletion of both G60 and C122 positions of the five samples were detected. We found same alterations in the five samples (16.6 %) in positions G60 and C122. In conclusion, these results suggest that the commonly found mutations in exon 9 of the DR5 gene may be one of the sensitive positions for tumorigenesis of the cancer.
Literatur
Zurück zum Zitat Amirijavid SH, Entezari M, Hashemi M (2014a) The anticancer effect of mouse antibodies produced against three nanoliposomal epitops of human DR5 on human breast cancer cells. AFINIDAD 80(566):205–209 Amirijavid SH, Entezari M, Hashemi M (2014a) The anticancer effect of mouse antibodies produced against three nanoliposomal epitops of human DR5 on human breast cancer cells. AFINIDAD 80(566):205–209
Zurück zum Zitat Amirijavid SH, Hashemi M, Akbarzadeh A (2014b) Cytotoxicity and anticancer activity of the IgY produced against an 21 aminoacids epitope of human DR5. AFINIDAD 80(568):387–392 Amirijavid SH, Hashemi M, Akbarzadeh A (2014b) Cytotoxicity and anticancer activity of the IgY produced against an 21 aminoacids epitope of human DR5. AFINIDAD 80(568):387–392
Zurück zum Zitat Ashkenazi A (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19:325–331CrossRefPubMed Ashkenazi A (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19:325–331CrossRefPubMed
Zurück zum Zitat Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4(1):34–41CrossRefPubMed Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4(1):34–41CrossRefPubMed
Zurück zum Zitat Chuaqui RF, Sanz-Ortega J, Vocke C, Linehan WM, Sanz-Esponera J, Zhuang Z, Emmert-Buck MR, Merino MJ (1995) Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas. Cancer Res 55:4995–4998PubMed Chuaqui RF, Sanz-Ortega J, Vocke C, Linehan WM, Sanz-Esponera J, Zhuang Z, Emmert-Buck MR, Merino MJ (1995) Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas. Cancer Res 55:4995–4998PubMed
Zurück zum Zitat Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205–2212CrossRefPubMed Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205–2212CrossRefPubMed
Zurück zum Zitat Koornstra JJ, Jalving M, Rijcken FE, Westra J, Zwart N, Hollema H, de Vries EG, Hofstra RW, Plukker JT, de Jong S, Kleibeuker JH (2005) Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 41:1195–1202CrossRefPubMed Koornstra JJ, Jalving M, Rijcken FE, Westra J, Zwart N, Hollema H, de Vries EG, Hofstra RW, Plukker JT, de Jong S, Kleibeuker JH (2005) Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 41:1195–1202CrossRefPubMed
Zurück zum Zitat Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Jang JJ, Han JY, Lee JY, Yoo NJ (1999) Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 59:5683–5686PubMed Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Jang JJ, Han JY, Lee JY, Yoo NJ (1999) Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 59:5683–5686PubMed
Zurück zum Zitat Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 20:399–403CrossRefPubMed Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 20:399–403CrossRefPubMed
Zurück zum Zitat Pai SI, Wu GS, Ozören N, Wu L, Jen J, Sidransky D, El-Deiry WS (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58(16):3513–8PubMed Pai SI, Wu GS, Ozören N, Wu L, Jen J, Sidransky D, El-Deiry WS (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58(16):3513–8PubMed
Zurück zum Zitat Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111–113CrossRefPubMed Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111–113CrossRefPubMed
Zurück zum Zitat Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, Park CH, Lee SK, Lee SH, Lee SN, Kim H, Yoo NJ, Lee JY (2001) Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121(5):1219–25CrossRefPubMed Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, Park CH, Lee SK, Lee SH, Lee SN, Kim H, Yoo NJ, Lee JY (2001) Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121(5):1219–25CrossRefPubMed
Zurück zum Zitat Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ Jr, el-Deiry WS (1998) P53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58(8):1593–8PubMed Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ Jr, el-Deiry WS (1998) P53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58(8):1593–8PubMed
Zurück zum Zitat Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327):818–21CrossRefPubMed Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327):818–21CrossRefPubMed
Zurück zum Zitat Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM (1996) Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12–21. Cancer Res 56:2411–2416PubMed Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM (1996) Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12–21. Cancer Res 56:2411–2416PubMed
Zurück zum Zitat Wei W, Liu Y, Zheng D (2005) Current understanding on the immunological functions of tumor necrosis factor-related apoptosis-inducing ligand. Cell Mol Immunol 2(4):265–9PubMed Wei W, Liu Y, Zheng D (2005) Current understanding on the immunological functions of tumor necrosis factor-related apoptosis-inducing ligand. Cell Mol Immunol 2(4):265–9PubMed
Zurück zum Zitat Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF (1999) Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 59:1973–1979PubMed Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF (1999) Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 59:1973–1979PubMed
Zurück zum Zitat Zhou J, Zhong Y (2004) Breast Cancer Immunotherapy. Cell Mol Immunol 1(4):247–255PubMed Zhou J, Zhong Y (2004) Breast Cancer Immunotherapy. Cell Mol Immunol 1(4):247–255PubMed
Metadaten
Titel
Mutation screening of exon 9 of DR5 receptor in patients with breast cancer using PCR-SSCP
verfasst von
Sh. Amirijavid
A. Akbarzadeh
S. Saghafi Jokar
S. Esmaeilian
E. Farahani
S. Ghassemi
Publikationsdatum
01.11.2015
Verlag
Springer London
Erschienen in
Comparative Clinical Pathology / Ausgabe 6/2015
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-015-2100-5

Weitere Artikel der Ausgabe 6/2015

Comparative Clinical Pathology 6/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …